Common Antidepressant Shows Promise for Long COVID…

Common Antidepressant Shows Promise for Long COVID Fatigue, Clinical Trial Finds Persistent fatigue remains one of the most common and debilitating symptoms of long COVID, affecting millions of people worldwide. Despite its impact on daily life, evidence-based treatment options have remained limited. Now, a randomized clinical trial published in the Annals of Internal Medicine suggests that fluvoxamine, a commonly prescribed antidepressant, may help reduce long COVID-related fatigue and improve quality of life. Researchers from McMaster University, in collaboration with institutions in Canada, Brazil, and the United States, conducted the REVIVE-TOGETHER trial involving 399 adults with persistent fatigue lasting at least 90 days after confirmed COVID-19 infection. Participants were randomly assigned to receive one of the following for 60 days: Fluvoxamine Metformin Placebo The primary objective was to determine whether either medication could improve fatigue associated with long COVID. The study found that participan